Hemophilia Market

Hemophilia Market Size by Disease Type (Hemophilia A, Hemophilia B), Therapy (Replacement Therapy, Gene Therapy), Product Type, Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2021 to 2028

Base Year: 2020 Historical Data: 2018-19
  • Report ID: TBI-12542
  • Published Date: Oct, 2021
  • Pages: 226
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

Global haemophilia market is expected to reach USD 18.88 billion by 2028, at a CAGR of 7.72% from 2021 to 2028. Global haemophilia market is witnessing a considerable growth owing to the growing prevalence of haemophilia across the globe.

Market Overview:

Haemophilia is considered generally an inherited bleeding disorder in which blood does not clot, or there is a problem in the clotting of blood. This can lead to spontaneous bleeding after a mere cut or bruise and even in the case of surgeries. Blood contains many proteins which are called clotting factors. This clotting factors are responsible for the clotting of blood. People who are suffering from haemophilia are either having low clotting factor VIII or low clotting factor IX. The severity of haemophilia depends on the level of clotting factors in the blood. Lower the level of clotting factors in the blood more will be the bleeding which could lead to serious health problems. In some cases, haemophilia shows symptoms late, or people develop this later in life like middle-aged and elderly person.  Women who have just given birth to a child or if she is in the later stage of pregnancy can also show symptoms. Such cases can be cured with proper treatment. People suffering from haemophilia should be careful as bleeding within joints can lead to chronic joint pain and disease, bleeding in the head can lead to seizures and paralysis, bleeding from vital organs can also be fatal if it can’t be stopped and lead to death. There are many types of Haemophilia. The two most common type of haemophilia is Haemophilia A, and Haemophilia B. Heamophilia A happens due to a lack of clotting factor VIII. Haemophilia B happens due to a lack of clotting factor IX. The best way for treatment is to replace the clotting factor. This way, blood start clotting. This replacement is done by infusion of factor concentrates. Currently, over 20,000 males are suffering from haemophila in US. Haemophilia A is four times more common compared to Haemophilia B. Half of the people suffering from Haemophilia are in serious form. According to the World Federation of Hemophilia record, 184,723 people were suffering from haemophilia in 2016.

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers:
  • Growing prevalence of haemophilia across the globe

According to the record 1 in every 5000 male birth is suffering from haemophilia, which prevents clotting of blood. In US every year 400 born babies are suffering from haemophilia. According to the World Federation of Hemophilia record, 184,723 people were suffering fromhaemophilia in 2016. According to WHO, there is higher chance of haemophilia in male when compared to women; this is due to sex linkage disorder. This is prevalent all across the globe. One of the record showed that 1/3rd of the diagnosed people have no family history for haemophilia.

  • Increasing investment in R&D and new product development

Cryoprecipitate use is the best way of stopping haemophilia bleeding.  But the recent technology called factor concentrates is the greatest breakthrough in such cases. This factor concentrates diagnose the patient suffering from haemophilia with greater efficiency. This revolutionary technology has made the treatment of the patient very easy, and so is the life of the patient. One can be easily treated at home or at work. Also, the investment in R&D and the development of new technologies like gene therapy and non-factor replacement therapy are driving the market.

Restraints:
  • High cost associated with haemophilia treatment

Haemophiliais connected with staggering direct costs from hospitalisations, outpatient visits, and drug treatments, as well as high indirect costs from diminished work productivity and absenteeism from work and school. Drugs are very expensive. Medications to treat haemophilia can cost up to an average of more than $270,000 annually per patient. In further complications, that yearly price tag can soar above $1 million. So this act as a restraint for haemophilia market.

Opportunities:
  • Increasing popularity and demand for gene therapy

Advancement and introduction of new medications and technologies such as non-factor replacement therapy, extended half-life products, gene therapy, etc. will boost the growth of haemophilia treatment market growth in the near future. Gene therapy provides a potential phenotypic cure for haemophilia, yet the cost of this novel treatment is high, tempering enthusiasm and raising questions regarding cost vs benefit.

Segmentation Analysis:

The global Hemophilia market has been segmented based on disease type, therapy, product type and regions.

  • Disease Type segment include haemophilia A, haemophilia B and others. The haemophiliaA segment held a substantial industry share of over 61.25% in 2020. Type A has been observed to be four times more widespread than type B. The pharmaceutical industries are flooded with drugs for the treatment of type A.  However, over the forecast period, the sector is expected to witness the fastest growth for type B-based medication, as showed there is a rise in the number of people being diagnosed with type B and by the increasing efforts to tackle it.
  • The therapy segment includes replacement therapy, gene therapy and others. Replacement therapy segment is accounted for the largest market share of around 76.27% in 2020. This is because replacement therapy is the first treatment recommended for patients suffering from moderate to severe haemophilia. Also, the investment in R&D would lead to the use of new drugs in replacement therapy. This is also driving the segment. Gene therapy is a growing field which focuses on identifying the defective DNA bases and then reinstating it with functional ones. Hence, this segment is anticipated to provide the most lucrative opportunities for the current players over the forecast period.
  • The product type segment includes Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others. Recombinant Coagulation Factor Concentrates segment accounted for the highest market value of USD 5.7 Billion in 2020. This is due to the fact that it has increased the safety in replacement therapy that has enhanced the quality of living for Hemophilia suffering patient. That’s why it has become the most preferred treatment. Moreover, the increase in the production of recombinant factor concentrates would provide a better opportunity for the market in the future.
Regional Segmentation Analysis:

The regions analyzed for the Haemophilia market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. North America region is accounted for the largest market share of 44.69% of the market in 2020.

  • High prevalence together with a rising inclination toward prophylaxis treatment, is predicted to be the preliminary drivers of this growth. According to the annual global survey, of WFH, it is estimated that about 64.0% of the patients in the U.S. have chosen for prophylaxis treatment, thereby propelling the growth.
  • However, over the forecast period, Asia-Pacific will show the fastest growth. Rise in the identification of cases in countries such as India, Indonesia, Japan, and Malaysia along with increasing use of therapies for factor VIII (type A) and IX (type B) deficiency are the vital impact rendering drivers.

North America Hemophilia Market Share in 2020- 44.69%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global Haemophilia industry.

For instance, in June 2016, Shire Plc acquired the Baxalta in June 2016. This is done to further expand the existent product portfolio of the company.

For instance, in March 2016, Baxalta filed an application for marketing authorization of Adynovi (Adynovate in the U.S.) with the EMA, which then was under the regulatory evaluation in Switzerland.

List of Key Market Players:

  • Baxalta
  • CSL Behring
  • Pfizer, Inc.
  • Bayer Healthcare
  • BioMarin Pharmaceutical, Inc.
  • Biogen
  • Chugai Pharmaceutical Co.
  • Novo Nordisk
  • Shire Plc.
  • Baxter International, Inc
  • Hospira Inc.

Key Target Audience

  • Hospitals
  • Clinics
  • Government Authorities
  • Research Organization

Report Description:

  • Global haemophilia Market, Industry Analysis, Trends, Analysis and Forecast, 2021 to 2028 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
  • 2020 is considered as the base year of the report. 2018 and 2019 are considered as the historic years and 2021 to 2028 are the forecast years. The global haemophilia market is based on revenue (USD Million/Billion), volume and price. The report incorporates the market study on the basis of revenue, and volume. The study covers the market share revenue/market share/volume for each of the segments, regions and countries catering to global haemophilia market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
  • The report encompasses with the relative data & information, which have been validated by the leading industry professionals and experts all across the globe. The research report also delivers an outline of the attractiveness of disease type, therapy, product type and regions which are deduced and formulated on the basis of their growth rate (CAGR), market size, and attractiveness by analyzing the present and future prospects to fathom market growth and development in future.
  • The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to global haemophilia market.  This offers vital and in depth insights in order to depict the overall market scenario.
  • The report offers the detailed study for the company profiles of key organizations operating in the global haemophilia market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development & innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario. 
  • The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis so as to provide business related data and information’s. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company growth and development in order to sustain and survive in the long run.
  • Along with that, the report also focuses on the market related driving factors, growth limitations (restraints), potential industry opportunities, significant trends and development which acts as a key potential for the investors. 
  • Potential growth prospects along with the penetration rate analysis of the products (market related i.e., global haemophilia market) is covered in order to comprehend the adoption rate and evaluate the market size.

Frequesntly Asked Questions

As per The Brainy Insights, the size of the hemophilia market was valued at USD 9.91 billion in 2020 and is anticipated to reach USD 18.88 billion by 2028.

Global hemophilia market is growing at a CAGR of 7.72% during the forecast period 2021-2028.

The global hemophilia market has been segmented based on disease type, therapy, product type and regions. Replacement therapy segment accounted for the largest market share in 2020.

The North America region emerged as the largest market for the hemophilia.

Growing prevalence of hemophilia across the globe is the key driving factor for the hemophilia market.

High cost associated with hemophilia treatment could hamper the market growth.

Increasing popularity and demand of gene therapy will provide huge opportunities to the market.

Key players are Baxalta, CSL Behring, Pfizer, Inc., Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co.

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Disease Type
          4.3.2. Market Attractiveness Analysis By Therapy
          4.3.3. Market Attractiveness Analysis By Product Type
          4.3.4. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Growing prevalence of hemophilia across the globe
          5.2.2. Increase in R&D and new product development
    5.3. Restraints
          5.3.1. High cost associated with hemophilia treatment
    5.4. Opportunities
          5.4.1. Increasing popularity and demand of gene therapy

6. Global Hemophilia Market Analysis and Forecast, By Disease Type
    6.1. Segment Overview
    6.2. Hemophilia A
    6.3. Hemophilia B
    6.4. Others

7. Global Hemophilia Market Analysis and Forecast, By Therapy
    7.1. Segment Overview
    7.2. Replacement Therapy
    7.3. Gene Therapy
    7.4. Others

8. Global Hemophilia Market Analysis and Forecast, By Product Type
    8.1. Segment Overview
    8.2. Recombinant coagulation factor concentrates
    8.3. Plasma-derived coagulation factor concentrates
    8.4. Others

9. Global Hemophilia Market Analysis and Forecast, By Regional Analysis
    9.1. Segment Overview
    9.2. North America
          9.2.1. U.S.
          9.2.2. Canada
          9.2.3. Mexico
    9.3. Europe
          9.3.1. Germany
          9.3.2. France
          9.3.3. U.K.
          9.3.4. Italy
          9.3.5. Spain
    9.4. Asia-Pacific
          9.4.1. Japan
          9.4.2. China
          9.4.3. India
    9.5. South America
          9.5.1. Brazil
    9.6. Middle East and Africa
          9.6.1. UAE
          9.6.2. South Africa

10. Global Hemophilia Market-Competitive Landscape
    10.1. Overview
    10.2. Market Share of Key Players in GlobalHemophilia Market
          10.2.1. Global Company Market Share
          10.2.2. North America Company Market Share
          10.2.3. Europe Company Market Share
          10.2.4. APAC Company Market Share
    10.3. Competitive Situations and Trends
          10.3.1. Product Launches and Developments
          10.3.2. Partnerships, Collaborations, and Agreements
          10.3.3. Mergers & Acquisitions
          10.3.4. Expansions

11. Company Profiles
    11.1. Baxalta
          11.1.1. Business Overview
          11.1.2. Company Snapshot
          11.1.3. Company Market Share Analysis
          11.1.4. Company Product Portfolio
          11.1.5. Recent Developments
          11.1.6. SWOT Analysis
    11.2. CSL Behring
          11.2.1. Business Overview
          11.2.2. Company Snapshot
          11.2.3. Company Market Share Analysis
          11.2.4. Company Product Portfolio
          11.2.5. Recent Developments
          11.2.6. SWOT Analysis
    11.3. Pfizer, Inc.
          11.3.1. Business Overview
          11.3.2. Company Snapshot
          11.3.3. Company Market Share Analysis
          11.3.4. Company Product Portfolio
          11.3.5. Recent Developments
          11.3.6. SWOT Analysis
    11.4. Bayer Healthcare
          11.4.1. Business Overview
          11.4.2. Company Snapshot
          11.4.3. Company Market Share Analysis
          11.4.4. Company Product Portfolio
          11.4.5. Recent Developments
          11.4.6. SWOT Analysis
    11.5. BioMarin Pharmaceutical, Inc.
          11.5.1. Business Overview
          11.5.2. Company Snapshot
          11.5.3. Company Market Share Analysis
          11.5.4. Company Product Portfolio
          11.5.5. Recent Developments
          11.5.6. SWOT Analysis
    11.6. Biogen
          11.6.1. Business Overview
          11.6.2. Company Snapshot
          11.6.3. Company Market Share Analysis
          11.6.4. Company Product Portfolio
          11.6.5. Recent Developments
          11.6.6. SWOT Analysis
    11.7. Chugai Pharmaceutical Co.
          11.7.1. Business Overview
          11.7.2. Company Snapshot
          11.7.3. Company Market Share Analysis
          11.7.4. Company Product Portfolio
          11.7.5. Recent Developments
          11.7.6. SWOT Analysis
    11.8. Novo Nordisk
          11.8.1. Business Overview
          11.8.2. Company Snapshot
          11.8.3. Company Market Share Analysis
          11.8.4. Company Product Portfolio
          11.8.5. Recent Developments
          11.8.6. SWOT Analysis
    11.9. Shire Plc.
          11.9.1. Business Overview
          11.9.2. Company Snapshot
          11.9.3. Company Market Share Analysis
          11.9.4. Company Product Portfolio
          11.9.5. Recent Developments
          11.9.6. SWOT Analysis
    11.10. Baxter International, Inc
          11.10.1. Business Overview
          11.10.2. Company Snapshot
          11.10.3. Company Market Share Analysis
          11.10.4. Company Product Portfolio
          11.10.5. Recent Developments
          11.10.6. SWOT Analysis
    11.11. Hospira Inc.
          11.11.1. Business Overview
          11.11.2. Company Snapshot
          11.11.3. Company Market Share Analysis
          11.11.4. Company Product Portfolio
          11.11.5. Recent Developments
          11.11.6. SWOT Analysis

List of Table

1.Global Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

2.Global Hemophilia A Hemophilia Market, By Region, 2018-2028 (USD Billion)

3.Global Hemophilia BHemophilia Market, By Region, 2018-2028 (USD Billion)

4.Global Others Hemophilia Market, By Region, 2018-2028 (USD Billion)

5.Global Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

6.Global Replacement Therapy, Hemophilia Market, By Region, 2018-2028 (USD Billion)

7.Global Gene Therapy, Hemophilia Market, By Region, 2018-2028 (USD Billion)

8.Global Others, Hemophilia Market, By Region, 2018-2028 (USD Billion)

9.Global Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

10.Global Recombinant Coagulation Factor Concentrates, Hemophilia Market, By Region, 2018-2028 (USD Billion)

Global Plasma-derived Coagulation Factor Concentrates, Hemophilia Market, By Region, 2018-2028 (USD Billion)

12.Global Others, Hemophilia Market, By Region, 2018-2028 (USD Billion)

13.Global Hemophilia Market, By Region, 2018-2028 (USD Billion)

14.Global Hemophilia Market, By North America, 2018-2028 (USD Billion)

15.North America Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

16.North America Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

17.North America Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

18.U.S. Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

19.U.S. Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

20.U.S. Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

21.Canada Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

22.Canada Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

23.Canada Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

24.Mexico Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

25.Mexico Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

26.Mexico Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

27.Europe Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

28.Europe Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

29.Europe Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

30.Germany Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

31.Germany Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

32.Germany Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

33.France Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

34.France Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

35.France Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

36.U.K. Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

37.U.K. Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

38.U.K. Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

39.Italy Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

40.Italy Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

41.Italy Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

42.Spain Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

43.Spain Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

44.Spain Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

45.Asia Pacific Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

46.Asia Pacific Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

47.Asia PacificHemophilia Market, By Product Type, 2018-2028 (USD Billion)

48.Japan Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

49.Japan Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

50.JapanHemophilia Market, By Product Type, 2018-2028 (USD Billion)

51.China Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

52.China Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

53.China Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

54.India Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

55.India Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

56.India Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

57.South America Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

58.South America Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

59.South America Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

60.Brazil Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

61.Brazil Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

62.Brazil Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

63.Middle East and Africa Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

64.Middle East and Africa Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

65.Middle East Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

66.UAE Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

67.UAE Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

68.UAE Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

69.South Africa Hemophilia Market, By Disease Type, 2018-2028 (USD Billion)

70.South Africa Hemophilia Market, By Therapy, 2018-2028 (USD Billion)

71.South Africa Hemophilia Market, By Product Type, 2018-2028 (USD Billion)

List of Figures 

1.Global Hemophilia Market Segmentation

2.Hemophilia Market: Research Methodology

3.Market Size Estimation Methodology: Bottom-Up Approach

4.Market Size Estimation Methodology: Top-Down Approach

5.Data Triangulation

6.Porter’s Five Forces Analysis

7.Value Chain Analysis

8.Global Hemophilia Market Attractiveness Analysis By Disease Type

9.Global Hemophilia Market Attractiveness Analysis By Therapy

10.Global Hemophilia Market Attractiveness Analysis By Product Type

11.Global Hemophilia Market Attractiveness Analysis By Region

12.Global Hemophilia Market: Dynamics

13.Global Hemophilia Market Share By Disease Type(2021 & 2028)

14.Global Hemophilia Market Share by Therapy(2021 & 2028)

15.Global Hemophilia Market Share by Product Type(2021 & 2028)

16.Global Hemophilia Market Share by Regions (2021 & 2028)

17.Global Hemophilia Market Share by Company (2020)

This study forecasts revenue at global, regional, and country levels from 2018 to 2028. The Brainy Insights has segmented the global Hemophiliamarket on the basis of below mentioned segments:

Global Hemophilia Market by Disease Type:

  • Hemophilia A
  • Hemophilia B
  • Others

Global Hemophilia Market by Therapy:

  • Replacement Therapy
  • Gene Therapy
  • Others

Global Hemophilia Market by Product Type:

  • Recombinant Coagulation Factor Concentrates
  • Plasma-derived Coagulation Factor Concentrates
  • Others

Global Hemophilia Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date